

APPENDIX: Claims pending upon entry of the amendment.

1. (amended) A method for inducing an immune response against transformed, infected or diseased tissue comprising
removing only components present in the blood having a molecular weight of 120,000 daltons or less, until the transformed, infected, or diseased tissue is reduced in amount.
2. The method of claim 1 wherein the tissue is a solid tumor.
3. The method of claim 1 wherein the components are removed from one blood volume.
4. The method of claim 1 wherein the components are removed in multiple treatments.
5. The method of claim 1 further comprising treating the tissue with an agent selected from the group consisting of anti-angiogenic compounds, procoagulant compounds, cytokines, chemotherapeutic agents, and radiation.
6. The method of claim 5 wherein the agent is a cytokine and the cytokine is selected from the group consisting of GM-CSF, erythropoietin, thrombopoetin, G-CSF, M-CSF and SCF.
7. The method of claim 1 further comprising selectively removing soluble TNF receptor 1 and receptor 2 molecules.
8. The method of claim 1 further comprising vaccinating the patient with a vaccine against the transformed, infected or diseased tissue.
9. (amended) A system for inducing an immune response against transformed, infected or diseased tissue comprising
a device for removing only components present in the blood having a molecular weight of 120,000 daltons or less[, and
an agent selected from the group consisting of anti-angiogenic compounds, procoagulant compounds, cytokines, chemotherapeutic agents, and radiation], having inlet and outlet means for connection to a pump and tubing to recirculate the blood of a patient through the device.
10. (amended) The [system] kit of claim [9] 17 wherein the agent is an anti-angiogenic compound.
11. (amended) The [system] kit of claim [9] 17 wherein the agent is a procoagulant compound.
12. (amended) The [system] kit of claim [9] 17 wherein the agent is a cytokine.
13. (amended) The [system] kit of claim 12 wherein the agent is a cytokine and the cytokine is selected from the group consisting of GM-CSF, erythropoietin, thrombopoetin, G-CSF, M-CSF and SCF.
14. (amended) The [system] kit of claim [9] 17 wherein the agent is a chemotherapeutic agent.
15. (amended) The [system] kit of claim 14 wherein the agent is selected from the group consisting of alkylating agents, doxyrubicin, carboplatinum, cisplatinum, and taxol.
16. (amended) The system of claim 9 wherein the [device] system includes means for administering radiation to the tissue.
Please add new claims 17-23.
17. A kit for treatment of a patient to induce an immune response against transformed, infected or diseased tissue comprising:
a device for removing only components present in the blood having a molecular weight of 120,000 daltons or less and

U.S. SERIAL NO.: 09/083,307
FILED: May 22, 1998
PRELIMINARY AMENDMENT

an agent selected from the group consisting of anti-angiogenic compounds, procoagulant compounds, cytokines, chemotherapeutic agents, and radiation, in a dosage formulation for treatment of the patient.

18. The system of claim 9 wherein the device is a capillary membrane filter with a pore size of between about 0.02 and 0.05 microns.

19. The system of claim 9 wherein the device is a parallel plate filter with a pore size of between about 0.04 and 0.08 microns.

20. The system of claim 9 wherein the device comprises filters with different pore sizes or geometries to provide for staggered removal of materials from the blood.

21. The system of claim 9 wherein the device is an absorbant colum selectively removing specific cytokine or cellular inhibitors from the blood.

22. The system of claim 9 wherein the blood is plasma.

23. The kit of claim 17 further comprising anticoagulant to treat the device for removal of components from the blood prior to use.